ReviewAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2017
Myeloma in Elderly Patients: When Less Is More and More Is More.
Review in American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.The oncologist · 2021Trial
- Article
- Liposomal nanoparticles as a drug delivery system for improved treatment of multiple myeloma.RSC advances · 2026Review
- Validating the Korean Geriatric Assessment Tool in Elderly Multiple Myeloma Patients: A Multicenter Study.Cancer research and treatment · 2026Article
- Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma.European journal of haematology · 2025Article
- Presentation, treatment and clinical outcomes in young multiple myeloma patients treated at a tertiary care centre in a low middle-income country.Ecancermedicalscience · 2025Article
- Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience.Blood advances · 2024Article
- Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- An overview of multiple myeloma: A monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities.Saudi journal of biological sciences · 2024Review
- Analysis of baseline circulating tumor cells integrated with PET/CT findings in transplant-ineligible multiple myeloma.Blood advances · 2024Article
- Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.The oncologist · 2022Article
- Metabolic Vulnerabilities in Multiple Myeloma.Cancers · 2022Review
- Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis.Blood cancer journal · 2022Observational
- Treatment of older adult or frail patients with multiple myeloma.Hematology. American Society of Hematology. Education Program · 2021Article
- Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects.Frontiers in medicine · 2021Review
- Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- COVID-19 and myeloma: what are the implications for now and in the future?British journal of haematology · 2020Article
- Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide.Clinical interventions in aging · 2020Review
- Gossypol induces apoptosis of multiple myeloma cells through the JUN-JNK pathway.American journal of cancer research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Multiple myeloma is a plasma cell malignancy that occurs among older adults and accounts for 15% of all hematologic malignancies in the United States. Thirty-five percent of patients are diagnosed at age 75 or older. Novel therapeutics and routine use of autologous stem cell transplantation (ASCT) have led to substantial improvements in patient survival, although improvements have been more impressive among patients younger than age 65. Finding the balance between under- and overtreating elderly patients is one of the biggest challenges specific to them as a subgroup of patients with MM. Decision making about which therapies and their dose intensity and duration should be influenced by a patient's functional status, personal preferences, disease characteristics, and ability to tolerate therapy. ASCT should be considered for all patients younger than age 80, assuming that they are not frail. The attainment of a stringent complete response and minimal residual disease negativity is associated with improved progression-free and overall survival. Again, consideration of quality of life for these patients is paramount. Although there is a growing list of tools to sort through these issues, a fully integrated approach has not yet been finely tuned, leaving additional work to be done for the treatment of elderly patients with MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.